IDEAYA Biosciences, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
IDEAYA submitted an NDA to FDA in Q3 2026 for darovasertib plus crizotinib in metastatic uveal melanoma under the RTOR program, supported by positive Phase 2 data presented at ESMO 2026. The company decided to stop enrollment in the Phase 3 OptimUM-010 neoadjuvant trial due to site activation/enrollment challenges, realizing estimated cost savings of $100–125 million to redirect toward IDE849 and IDE892 registrational trials. Cash position: $1.15B as of September 30, 2026 (down from $1.24B on June 30, 2026); cash runway guidance into 2030 unchanged.
Why this rating
NDA submission is significant milestone for lead asset; trial closure reduces burn but signals execution challenge. Net savings ~7–11% of market cap is material, though offset by runway extension into 2030 and pipeline momentum.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.